Joel Weadge is an Associate Professor in the Biology Department at Wilfrid Laurier University , Waterloo, Ontario. His research focuses on bacterial biofilms, glycobiology, and protein structure-function relationships. Contact: jweadge@wlu.ca , Office: BA425 (Bricker Academic). Education: PhD in Microbiology (University of Guelph, 2006) BSc (Hons) in Microbiology (University of Guelph, 2000) Research Interests center on bacterial biofilms as virulence factors in pathogens like E. coli and Salmonella . Key areas include: Structural and functional characterization of biofilm proteins (cellulose, curli fimbriae) Enzymology of carbohydrate modifications (acetylation, phosphoethanolamine transfer) Developing therapeutics targeting biofilm synthesis Biopolymer applications for medical/industrial use Publications highlight studies on Pseudomonas and Salmonella biofilm mechanisms, glycosyltransferases, and carbohydrate-active enzymes, with methodologies spanning X-ray crystallography to high-throughput biofilm profiling. Labs and Teams: The Weadge Lab investigates biofilm roles in food/water security and oral health, utilizing enzymology, mass spectrometry, and structural biology. Current members include graduate students, technicians, and research assistants.
Aditi Das is a Full Professor in the School of Chemistry and Biochemistry at the Georgia Institute of Technology, College of Sciences. She leads the Das Laboratory, which focuses on the biochemistry and chemical biology of lipids, particularly studying cytochrome P450 enzymes and their role in lipid metabolism, endocannabinoid systems, and inflammatory pathways. Her educational background includes: B.Sc. in Chemistry from St. Stephen's College M.Sc. in Chemistry from Indian Institute of Technology, Kanpur (I.I.T) Ph.D. in Chemistry from Princeton University Postdoctoral research at Northwestern University (NSF-NSEC fellow) and Beckman Institute for Advanced Science and Technology, University of Illinois UC Professor Das's research interests center around understanding the physiological role of lipids in sustaining homeostasis and their implications in disease states such as neurodegenerative disorders, cancer, and cardiovascular diseases. Her laboratory specializes in: Enzymology of cytochrome P450s, particularly CYP2J2 epoxygenase Metabolism of ω-3 and ω-6 fatty acids and their derivatives Minor cannabinoid metabolism by cytochrome P450 enzymes Discovery of novel anti-inflammatory lipid metabolites and endocannabinoids Mechanistic studies of membrane proteins using nanodisc technology Her work bridges biochemistry, chemical biology, and pharmacology to uncover novel therapeutic targets related to lipid signaling pathways. Analysis of Professor Das's recent publications (2023-2025) reveals a strong focus on cannabinoid metabolism by cytochrome P450 enzymes, with particular emphasis on how these metabolic processes generate bioactive compounds that interact with the endocannabinoid system. Her research increasingly explores the therapeutic potential of omega-3 derived endocannabinoid epoxides in inflammatory and neurodegenerative conditions. The use of nanodisc technology for studying membrane proteins in near-native environments remains a consistent methodological thread throughout her work, enabling detailed mechanistic insights into enzyme function. Professor Das has received numerous prestigious awards recognizing her research excellence and teaching: 2024 NIH Outstanding Researcher Award (MIRA R35) for established investigators 2024 Vasser Woolley Faculty Fellowship 2023 Plenary Lecture at the International Society of the Study of Xenobiotics (ISSX) 2021 E.L.R. Stokstad Award 2019-2021 List of Teachers Ranked as Excellent 2019 Eicosanoid Research Foundation Young Investigator Award 2019 Zoetis Research Excellence Award 2019 Mary Swartz Rose Young Investigator Award 2015 National Scientist Development Award from the American Heart Association 2022 El Sohly Award from the American Chemical Society Professor Das actively mentors a diverse group of students and postdoctoral researchers, with several former lab members now holding faculty positions or working at prestigious institutions. Her laboratory has secured significant funding from NIH, NSF, and other sources to support research on lipid metabolism, cannabinoid pharmacology, and membrane protein biochemistry. Notable grants include an NIH R35 Outstanding Investigator Award (MIRA), an NIH R21 grant from NIDA, and multiple collaborative grants with other research groups. The Das Laboratory operates within the Petit Institute of Bioengineering and Biosciences (IBB) at Georgia Tech, utilizing state-of-the-art facilities for biochemical and biophysical studies. The lab specializes in nanodisc technology to study membrane proteins in near-native environments, with particular expertise in cytochrome P450 enzymes and their interactions with lipid substrates. Recent work has expanded into collaborative projects involving lipidomics, structural biology, and translational applications of lipid signaling research.
Professor Thomas Meier is a Visiting Professor at the Department of Life Sciences, Imperial College London (since 2015), and Director of the Centre for Structural Biology (2017–2021). He leads research on ATP synthase structure, drug targets for tuberculosis, and molecular mechanisms of disease. Previously, he was a Group Leader at the Max-Planck-Institute of Biophysics (2006–2015) and ETH Zurich's Institute of Microbiology. His work combines structural biology (X-ray crystallography, electron microscopy) with biochemical studies. Education: Dr. sc. nat. (2002) and Dipl. sc. nat. (1998) from ETH Zurich. Awards include the Wellcome Trust Investigator (2015–present). Research focuses on ATP synthase's role in energy conversion, drug development, and structural biology. His lab includes postdocs and students like Lisa Uhrig and Anthony Cheuk. Key affiliations: Centre for Structural Biology, Membrane Biology Group, and Bacterial Pathogenesis studies. Languages: German, English, French (fluent), Latin (read/write). Publications span structural biology, planetary science, and drug discovery. His work on ATP synthase inhibitors for TB has clinical implications, while astrophysical studies explore planetary formation via giant impacts.
Prof. Veronika Somoza is a leading academic in Nutritional Systems Biology, currently affiliated with the University of Vienna and Technical University of Munich (TUM). She holds a professorship in Molecular Food Science and has led key research groups such as the Institute of Physiological Chemistry and the Christian Doppler Laboratory for Bioactive Aromatics. Her career includes roles at institutions like the German Research Institute for Food Chemistry (Garching) and the University of Wisconsin-Madison. Education: Diplom (Justus Liebig University Giessen, 1991), PhD (University of Vienna, 1995), Habilitation (Kiel University, 2002) Research Focus: Bioactive food compounds, flavor chemistry, taste receptor signaling, and gastrointestinal physiology Her work bridges food science and human health, particularly in understanding how food ingredients influence digestion, inflammation, and disease. Notable contributions include discoveries on bitter peptide effects on gastric acid secretion and flavor perception modulation. Awards: FEMA Excellence in Flavor Science (2016), ACS AGFD Fellow (2020), Hans Adolf Krebs Prize (2004) Prof. Somoza has pioneered methodologies in atomic force microscopy for foodborne virus detection and developed bitterness-masking compounds for pharmaceuticals. Her interdisciplinary approach integrates nanobiophysics with nutrition to advance functional food design and clinical applications.
Nancy J. Brown, M.D., is the Jean and David W. Wallace Dean of the Yale School of Medicine and holds the C.N.H. Long Professorship in Internal Medicine. Previously, she served as Chair of Vanderbilt Department of Medicine and Physician-in-Chief of Vanderbilt University Medical Center (2010–2020). Her academic career spans over three decades, with leadership roles in clinical care, research, and medical education. Education: MD, Harvard University (1986) AB in Molecular Biophysics and Biochemistry, Yale College (1981) Internship and Residency in Medicine, Vanderbilt University (1989) Fellowship in Clinical Pharmacology, Vanderbilt University (1991) Chief Resident, Vanderbilt University (1992) Research Interests: Dr. Brown’s work focuses on the renin-angiotensin-aldosterone system’s role in cardiovascular disease, hypertension, and thrombosis. Her lab has elucidated mechanisms linking aldosterone, bradykinin, and ACE inhibitors to inflammation, fibrosis, and cardiovascular risk. Current studies explore neprilysin inhibitors in heart failure and incretin-based therapies’ cardiovascular effects. Key Contributions: Identified genetic variants and African ancestry as risk factors for ACE inhibitor-associated angioedema Developed Vanderbilt’s Master of Science in Clinical Investigation program (2000) Advocated for physician-scientist development through leadership roles in NIH councils and professional organizations Recognition: Recipient of the Harriet Dustan Award, August M. Watanabe Prize, and Robert H. Williams Distinguished Chair of Medicine. Elected to the National Academy of Medicine and American Academy of Arts & Sciences. Labs/Teams: Leads the Yale School of Medicine’s cardiovascular research initiatives, focusing on translational studies of RAAS pathways and drug mechanisms.
Carla P. Gomes is a Professor of Computer Science at Cornell University with joint appointments in the Department of Computer Science and the Dyson School of Applied Economics and Management. She holds a PhD in computer science from the University of Edinburgh and an M.Sc. in applied mathematics from the University of Lisbon. Her research focuses on artificial intelligence, constraint reasoning, optimization, and computational sustainability. As Director of the Institute for Computational Sustainability (ICS) and co-director of the Cornell University AI for Science Institute, she leads efforts to integrate AI with sustainability challenges. Her research themes include the integration of constraint reasoning, machine learning, and operations research to solve large-scale problems. She pioneered the field of Computational Sustainability, addressing environmental, economic, and societal challenges through AI. Gomes directed two NSF Expeditions in Computing awards and established CompSustNet, a large-scale sustainability research network. Key awards include the 2021 ACM–AAAI Allen Newell Award, AAAI Feigenbaum Prize, and fellowships from AAAI, ACM, and AAAS. Her work spans over 200 publications, with contributions to AI, sustainability, and materials discovery. She advises numerous PhD students and oversees postdocs in AI, sustainability, and interdisciplinary projects. Gomes' lab focuses on AI for scientific discovery, including autonomous materials synthesis and crystal-structure phase mapping. She collaborates with institutions like JCAP and the Materials Project, advancing AI-driven solutions for energy and environmental challenges. Current projects include Schmidt AI in Science postdoc initiatives and AI-driven materials discovery platforms like DRNets and SARA.
Dr. Anil Kumar is an Assistant Professor in the Department of Biochemistry, Microbiology & Immunology at the University of Saskatchewan's College of Medicine. He specializes in molecular virology, focusing on positive-stranded RNA viruses and their interactions with host immune systems. His research employs high-throughput genetic screens and reverse genetics systems to identify host factors critical for viral infection. Education includes a BSc in Agricultural Sciences (1999, Kerala Agricultural University), MSc in Plant Pathology (2001, Indian Agricultural Research Institute), and PhD in Molecular Virology (2010, University of Heidelberg). Postdoctoral training included stints at the University of Heidelberg (2010–2013) and the University of Alberta (2014–2020). Research interests center on Eastern Equine Encephalitis virus (EEEV) and Enterovirus D68 (EV-D68). For EEEV, his lab investigates immune evasion mechanisms and host-virus protein interactions to identify therapeutic targets. For EV-D68, they study CNS invasion mechanisms and novel host dependency factors linked to acute flaccid myelitis (AFM). Recent work includes studies on SARS-CoV-2, uncovering roles for host proteins like Argonaute 2 in viral restriction. His lab integrates molecular biology, virology, and systems biology approaches, with a focus on translational research for antiviral drug development. Collaborations include work on respiratory syncytial virus (RSV) entry mechanisms and dengue virus replication regulation.
Professor Marek Sanak serves as Full Professor at the Department of Internal Medicine, Jagiellonian University Medical College in Cracow, Poland. He concurrently holds leadership positions as Acting Director of the Department of Forensic Medicine, Head of the Division of Molecular Biology and Clinical Genetics, and Vice-Rector for Research and International Cooperation since 2016. His academic foundation includes: MD from Jagiellonian University Medical College Specialization in Pediatrics and Genetics PhD from Jagiellonian University Research appointments at Harvard University, University of Paris VI, and University of Zurich Professor Sanak's research integrates clinical genetics with molecular immunology, focusing on asthma pathogenesis, lipid mediators of inflammation, and genetic diagnostics. His laboratory employs advanced techniques including deep DNA/RNA sequencing to identify biomarkers and elucidate disease mechanisms. The work bridges fundamental molecular discoveries with clinical applications in respiratory diseases, allergic disorders, and forensic medicine, demonstrating particular expertise in aspirin-exacerbated respiratory disease and epigenetic regulation of inflammatory pathways. Analysis of his recent publications reveals a strategic evolution from classical asthma research toward molecular genetics and viral pathogenesis. His 2017-2021 work increasingly incorporates epigenetic approaches (DNA methylation, microRNA profiling) while expanding into SARS-CoV-2 research during the pandemic. The publications demonstrate interdisciplinary integration across immunology, respiratory medicine, and molecular diagnostics, with consistent focus on translational applications. His distinguished career has been recognized through numerous honors: The Lancet Investigators Award on Asthma (1997) Polish Ministry of Health Individual Prize (1999) Jagiellonian Laurel (2012) Pro Arte Docendi Award (2014/15) Gold Medal for Long Service (2019) Top 2% of world scientists ranking (Elsevier 2022) As Vice-Rector for Research, Professor Sanak has significantly expanded international collaborations with King's College London, University of Southampton, and University of Zurich. His leadership has secured substantial funding for molecular diagnostics and inflammatory disease research while mentoring numerous early-career researchers. He delivers invited lectures globally for organizations including the American Thoracic Society and European Academy of Allergy and Clinical Immunology. Professor Sanak directs integrated research units across the Division of Molecular Biology and Clinical Genetics, Division of Biochemical and Molecular Diagnostics at University Hospital Cracow, and the Department of Forensic Medicine. These teams combine clinical service with basic research to advance genetic diagnostics and understand disease mechanisms, maintaining forensic genetics expertise developed over 20 years of practice.
Staffan Kjelleberg is a Distinguished University Professor at Nanyang Technological University (NTU), Singapore, and Director of the Singapore National Biofilm Consortium (SNBC) and Singapore Centre for Environmental Life Sciences Engineering (SCELSE). He holds previous positions as Scientia Professor at the University of New South Wales (UNSW), Australia, and has led major research initiatives globally. His academic career spans over four decades, with roles including Head of School at UNSW and Professorships at the University of Gothenburg, Sweden. Education: BSc (Chemistry and Biology, 1975), PhD (Microbiology, 1981), and Docent (Microbiology, 1983) from the University of Gothenburg. He has authored over 384 journal papers with significant citations, reflecting his leadership in microbial biofilm research. Research focuses on microbial biofilms and microbiomes, addressing environmental sustainability, public health, and industrial applications. He employs an interdisciplinary approach to study biofilm community dynamics, matrix properties, and translational technologies for biofilm control. Key contributions include discoveries on quorum sensing inhibitors, biofilm dispersal mechanisms, and eDNA roles in biofilm structure. Honours include Fellowships from the Australian and American Academies of Microbiology, Web of Science Highly Cited Researcher status, and Editor roles for 15 international journals. He leads major programs like the Marine Climate Change Science initiative and has co-directed global research centers such as the Centre for Marine Bio-Innovation. Advising and grants: While specific student names are not listed, his extensive leadership in research programs indicates mentorship of numerous scholars. His work bridges fundamental and applied microbiology, impacting environmental and biomedical fields. Labs/Teams: Directs SCELSE and SNBC, co-founded the Centre for Marine Bio-Innovation, and collaborates internationally on biofilm and microbiome research.
Senior Lecturer Outi Salo-Ahen is affiliated with Åbo Akademi University's Faculty of Natural Sciences and Engineering , Department of Pharmacy. Her research focuses on computational pharmacology, drug design, and pharmaceutical chemistry, particularly targeting chemokine receptors (CCR5/CXCR4) and transient receptor potential channels (TRPA1) for therapeutic applications. Doctor of Pharmacy (2006, University of Kuopio/UEF) MSc in Pharmaceutical Chemistry (2001, UEF) BSc in Pharmacy (1999, UEF) University Pedagogy Modules 1-5 (2012-2015) Her work contributes to UN Sustainable Development Goals through education and pharmaceutical innovation . Recent research trends include: Antimicrobial resistance solutions TRPA1 channel modulation Nanotechnology-enabled drug delivery Multi-target HIV-1 inhibitors 3D printing of biocompatible materials Computational analysis of nucleic acid frameworks She actively supervises doctoral projects, serves on assessment panels, and leads collaborations like Nordic Pharmaceutical Translation and Innovation. Her 60+ publications demonstrate expertise in molecular modeling and drug discovery.
Santiago F. González is a Group Leader at the Institute for Research in Biomedicine (IRB) in Bellinzona, Switzerland, and an extraordinary professor at the University of Italian Switzerland (USI). He earned dual PhDs in microbiology (University of Santiago de Compostela, Spain) and immunology (University of Copenhagen, Denmark), followed by postdoctoral work (2007–2011) at Harvard Medical School's Immune Disease Institute under Michael Carroll. PhD in Microbiology, University of Santiago de Compostela PhD in Immunology, University of Copenhagen His research focuses on immune system dynamics during respiratory viral infections, vaccination, and cancer metastasis. Key areas include influenza recognition , lymph node inflammation , and immune cell behavior in vivo. He pioneered studies on C-type lectin receptors (e.g., SIGN-R1) in viral immunity and epigenetic modulators for inflammation. Recent publications highlight his work in epigenetic drug development , nanovaccines , and computational tools for immune cell tracking. His group uses two-photon intravital microscopy and spatial-temporal modeling to dissect immune responses. Scientific awards include three EU Marie Curie Fellowships (2004–2013), enabling his transition to independent research. His collaborations span Harvard, USI, and European institutions, with grants from the EU and Swiss research bodies. His lab at IRB, established via the 2013 Marie Curie Career Integration Grant , develops novel imaging approaches and therapeutic strategies for infectious and immune-mediated diseases.
Prof. Dr. Markus Meissner is a Professor at the Faculty of Veterinary Medicine, Ludwig Maximilian University of Munich, leading the Chair of Experimental Parasitology. His research focuses on the molecular mechanisms of host cell invasion and modulation by Apicomplexan parasites, particularly Toxoplasma gondii and Plasmodium species. Research Group: Meissner Laboratory Location: Lena-Christ-Str. 48, 82152 Planegg-Martinsried Contact: markus.meissner@lmu.de His work investigates the secretory pathway of parasites, vesicular trafficking systems, and essential genes involved in host cell invasion and intracellular development. Toxoplasma gondii serves as a model organism for studying Apicomplexan biology, including nuclear division and CRMP complex functionality. Recent publications highlight the role of Rab GTPases in protein trafficking, chromatin remodeling in Plasmodium, and actin dynamics in parasite motility. Articles span topics such as egress factors, Golgi pathways, and lineage-specific organelle emergence, reflecting a multidisciplinary approach combining molecular biology, cell biology, and evolutionary analysis. The Meissner Lab includes PhD students (Peipei Qin, Yuan Song, Ella Schadt, Vitoria Catschor dos Santos) and postdocs (Dr. Wei Li, Dr. Miriam Rafajlovic). Research is conducted in Lena-Christ-Str. 48, Planegg-Martinsried, with a focus on experimental systems for studying parasite mechanisms.
Dr. Paula Gonzalez-Figueroa is a Research Fellow at the Clinical Hub for Interventional Research (CHOIR) in the College of Health and Medicine at The Australian National University (ANU). She holds a PhD in Medical Sciences from ANU and completed postdoctoral research at the John Curtin School of Medical Research (ANU) and the Francis Crick Institute (UK). Her research focuses on immunology, autoimmunity, allergy, and clinical translation. Education: PhD in Medical Sciences (ANU), Biotechnology degree. Research Interests: Regulatory T cells, germinal centers, B cell biology, neuritin-based therapies, preclinical drug testing, and early-phase clinical trials. Affiliations: CHOIR (Researcher), Polizzotto Group, Genome Sciences and Cancer Division. Her work includes developing a neuritin-based biotherapeutic for allergies and autoimmune diseases, and leading preclinical/Phase I clinical programs for hematological cancers. She has contributed to studies on Tfr cell regulation, IgE responses, and germinal center dynamics. Publications span immunology, molecular biology, and translational research, with notable contributions to Nature Immunology , Cell , and Journal of Experimental Medicine .
Simon Sharpe is a Professor in the Department of Biochemistry at the University of Toronto and a Senior Scientist at The Hospital for Sick Children. His research focuses on the structural and dynamic properties of self-assembling proteins, particularly those involved in degenerative diseases, elastomeric proteins, and biological phase separation. The Sharpe Lab utilizes advanced biophysical techniques such as NMR spectroscopy, X-ray scattering, and electron microscopy to investigate these phenomena. BSc: Memorial University of Newfoundland (Cell Biology and Biochemistry, 1997) PhD: University of Western Ontario (Biochemistry, 2002) Postdoctoral Training: NIH (Solid-State NMR, 2002-2006) Research interests include: Protein self-assembly mechanisms Amyloid formation in neurodegenerative diseases Elastin and resilin biophysics Lipid-protein interactions Biological phase separation Structure-function relationships Lab members include Research Associate Dr. Sean Reichheld and PhD students James Otis, Asal Nady, and Robert Lu. The lab has dedicated access to 600 and 700 MHz NMR spectrometers and collaborates with SickKids facilities including the SBC Facility and Imaging Facility. Scientific awards: Canada Research Chair (2006-2016) Ontario Early Researcher Award (2010) Dr. Sharpe has taught courses including BCH374Y1 (Research Project in Biochemistry) and BCH425H (Structural Biology: Principles and Practice). His recent publications examine topics ranging from serum amyloid A structure to bacterial phase separation defenses, with methodologies combining solid-state NMR, fluorescence microscopy, and computational approaches.
Maria J. Redondo is a Professor at Baylor College of Medicine and leads the Maria J. Redondo Lab at Texas Children’s Hospital, focusing on Type 1 Diabetes across four core areas: Genetics for prediction models and trial candidate selection Heterogeneity in diabetes pathogenesis Prevention through clinical trials Atypical Diabetes and Racial/Ethnic Influences Research Trends: Her recent articles emphasize genetic risk modeling, BMI correlations in pediatric diabetes, and HLA studies. The work integrates autoimmunity , metabolic research , and epidemiological analysis . Scientific Awards: Elected to the Society for Pediatric Research (2014) JDRF Early Career Development Award (2002) JDRF Postdoctoral Fellowship (2000) Immunology of Diabetes Society Junior Investigator Award (1998) Mentoring: Dr. Redondo mentors fellows and students in projects like COVID-19 and Diabetes and Racial Differences in Insulin Pump Uptake , with grants from NIH , Medtronic , and Hemsley Charitable Trust .
